| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
6,733 |
5,341 |
$182K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
25,637 |
19,478 |
$168K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
3,007 |
2,126 |
$147K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,190 |
2,151 |
$70K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
5,752 |
3,373 |
$52K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,030 |
1,985 |
$38K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
604 |
448 |
$38K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,073 |
928 |
$14K |
| 87428 |
|
715 |
463 |
$14K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
108 |
104 |
$12K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,106 |
778 |
$9K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
268 |
230 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
274 |
219 |
$5K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
272 |
215 |
$5K |
| 99441 |
|
181 |
178 |
$3K |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
185 |
179 |
$3K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14 |
13 |
$454.91 |
| 0004A |
|
43 |
40 |
$199.60 |
| 36415 |
Collection of venous blood by venipuncture |
59 |
56 |
$0.00 |